IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

Core Insights - IDEAYA Biosciences has initiated a Phase 1 trial for IDE034, a bispecific TOP1 ADC targeting B7H3/PTK7, which is co-expressed in 30-40% of various solid tumors, including lung, breast, ovarian, and colorectal cancers [1] - The trial aims to evaluate the safety, tolerability, and pharmacokinetics of IDE034, both as a monotherapy and in combination with the proprietary PARG inhibitor, IDE161 [1] - The first patient dosing triggers a $5 million milestone payment to Biocytogen, highlighting the collaboration between the two companies [1] Company Overview - IDEAYA Biosciences is focused on precision medicine in oncology, aiming to develop transformative therapies for cancer through a combination of small-molecule drug discovery, structural biology, and bioinformatics [1] - The company has a robust pipeline of product candidates, particularly in synthetic lethality and antibody-drug conjugates (ADCs), targeting molecularly defined solid tumor indications [1] - IDE034 represents the second proprietary TOP1 ADC from IDEAYA, following IDE849, which is currently in Phase 1 for small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) [1] Clinical Development - The Phase 1 trial will assess IDE034's potential as a first-in-class therapy, with preclinical models showing promising efficacy and synergy when combined with IDE161 [1] - The design of IDE034 allows for internalization only when both target antigens are present on the same tumor cell, potentially enhancing selectivity and tolerability compared to traditional antibody formats [1] - IDEAYA estimates minimal dual antigen expression in normal tissues, which may further improve the therapeutic profile of IDE034 [1]